What is Evolent Health's Story?
Evolent Health, founded in 2011, is a healthcare company focused on value-based care. It helps providers shift from fee-for-service to outcome-based models.
The company aims to improve population health and control costs by integrating clinical and administrative functions. Evolent Health specializes in managing complex conditions like oncology and cardiology.
What is Brief History of Evolent Health Company?
Evolent Health began with a vision to support healthcare systems in adopting value-based care. By 2024, its total revenue reached $2.55 billion, marking a 30.1% increase from the prior year. This growth highlights its success in the healthcare technology and services sector, particularly in enabling value-based care. For a deeper understanding of its market position, consider an Evolent Health Porter's Five Forces Analysis.
What is the Evolent Health Founding Story?
The Evolent Health company background traces back to its founding in 2011 by Frank Williams, Seth Blackley, and Dr. Tom Peterson. These co-founders brought together significant expertise in both healthcare and technology to address critical challenges in the industry.
Evolent Health Founding Story
Evolent Health was established in 2011 by Frank Williams, Seth Blackley, and Dr. Tom Peterson, aiming to solve inefficiencies in healthcare management. The company emerged as a joint venture between The Advisory Board Company and UPMC, combining their strengths to navigate the shift towards value-based care.
- Co-founded in 2011 by Frank Williams, Seth Blackley, and Dr. Tom Peterson.
- Established as a joint venture between The Advisory Board Company and UPMC.
- Focused on enabling population health management and value-based care transitions.
- Secured $100 million in Series B financing on September 30, 2013, bringing total funding to $124.5 million.
The founders recognized a critical need for enhanced infrastructure to manage population health effectively and support the transition from traditional fee-for-service models to value-based care. This insight formed the core of the Evolent Health mission. The company was initially structured as a joint venture, drawing upon the extensive knowledge and resources of The Advisory Board Company and UPMC.
The initial business model of Evolent Health focused on delivering a comprehensive suite of services. These included population health management, support for value-based care initiatives, and revenue cycle management. The goal was to equip healthcare organizations with the tools and strategies necessary to thrive in a value-based healthcare environment. Early offerings encompassed clinical and administrative solutions, risk adjustment services, and performance analytics, all designed to improve patient outcomes and streamline care delivery.
The early years of Evolent Health saw significant financial backing, with The Advisory Board Company providing initial funding. A pivotal moment in the Evolent Health company timeline was the Series B financing round on September 30, 2013, which raised $100 million. This infusion of capital brought the total funding to $124.5 million and welcomed TPG Growth as a new investor alongside the founding organizations. The name 'Evolent' itself was deliberately chosen to signify the company's commitment to evolution and adaptability within the ever-changing healthcare landscape. Understanding the Brief History of Evolent Health provides context for its current market position and strategic direction.
Evolent Health SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
What Drove the Early Growth of Evolent Health?
Following its founding, Evolent Health rapidly established its value-based care solutions through early partnerships with major health systems like Piedmont Healthcare and WellStar Health System. The company prioritized talent acquisition, recognizing its importance for client relations and operational success.
Founding and Early Partnerships
Evolent Health began by forging crucial partnerships with prominent health systems, including Piedmont Healthcare, WellStar Health System, Indiana University Health, MedStar Health, and Premier Health. This foundational period focused on building the core of its value-based care offerings.
Talent Development Focus
An early strategic investment was made in senior leadership to develop robust talent and career development programs. This initiative was key to attracting skilled professionals and enhancing the company's appeal to clients.
Public Offering and Market Entry
A significant milestone was the company's Initial Public Offering (IPO) in 2015 on the New York Stock Exchange, which raised $195 million. This event quickly propelled the company's market capitalization to over $1 billion, marking a strong public debut.
Strategic Acquisitions and Expansion
The company expanded its capabilities through strategic acquisitions, notably Valence Health in 2016 and New Century Health for $217 million, a specialty care management firm. In November 2022, NIA was acquired from Centene Corporation for $650 million upfront, bolstering its specialty care segment.
Technological Advancement and Rebranding
In June 2024, the company agreed to acquire AI utilization management assets from Machinify to enhance its technological offerings. A strategic rebranding in June 2023 unified its various solutions, including New Century Health and NIA, under the single 'Evolent' brand.
Robust Growth and Client Retention
The company reported 2024 revenue of $2.55 billion, a 30.1% increase from 2023, while maintaining 100% contract retention with its key clients. Early 2025 saw the signing of five new contracts adding approximately 1 million covered lives and $10 million in annual revenue.
Evolent Health PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
What are the key Milestones in Evolent Health history?
Evolent Health has navigated a path marked by significant achievements and considerable hurdles. The company's journey includes the development of its proprietary Identifi® Platform, offering advanced analytics and workflow solutions for healthcare providers. A notable innovation is its AI-powered Auth Intelligence platform, designed to streamline pre-authorization processes, with projections to reduce administrative costs by 20-30%. Evolent has also been recognized nationally as a top workplace in healthcare.
| Year | Milestone |
|---|---|
| Undisclosed | Development of the proprietary Identifi® Platform. |
| Undisclosed | Introduction of the AI-powered Auth Intelligence platform. |
| Ongoing | Consistent national recognition as a top place to work in healthcare. |
Evolent Health's innovations are centered on leveraging technology to enhance healthcare delivery and efficiency. The Identifi® Platform provides advanced analytics and workflow capabilities, while the AI-powered Auth Intelligence platform aims to significantly cut administrative costs in high-cost specialties. The company is also developing the Careology App for real-time symptom management, with a target to serve 300,000 members by 2026.
Identifi® Platform
Provides advanced analytics and workflow capabilities for healthcare providers, enhancing operational efficiency.
AI-Powered Auth Intelligence
Streamlines pre-authorization processes for high-cost specialties, aiming for significant administrative cost reductions.
Careology App
Designed for real-time symptom management, with a goal to support 300,000 members by 2026.
Top Workplace Recognition
The company consistently receives national accolades for its work environment in the healthcare sector.
Evolent Health has encountered significant challenges, including elevated oncology expenses that impacted its financial performance in 2024, resulting in a net loss of $93.5 million for the year. The first half of 2025 saw a revenue decrease to $647.145 million from $927.977 million in H1 2024, with net losses widening to $(123.340) million. The company also faces regulatory complexities, market consolidation, and the need to attract and retain skilled talent.
Financial Performance Decline
Elevated oncology expenses led to negative margins and substantial net losses in 2024 and the first half of 2025. Revenue saw a significant drop from H1 2024 to H1 2025.
Debt and Liquidity Concerns
A considerable debt load and a sharp decrease in cash reserves have presented substantial obstacles. The company has $647.5 million in long-term debt against $151 million in cash reserves as of Q2 2025.
Strategic Adjustments
In response, Evolent Health has renegotiated contracts, secured an anticipated $115 million annual improvement in Adjusted EBITDA for 2025, and is investing approximately $35 million in capitalized software development for 2025. Leadership changes and cost-cutting measures, including an $11.3 million reduction in SG&A expenses in Q2 2025, have also been implemented.
Debt Refinancing
The company refinanced its 2025 convertible notes with $145 million of convertible senior notes due 2031, repurchased $40 million in Class A stock, and reduced annual interest expense by over $9 million.
Evolent Health Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What is the Timeline of Key Events for Evolent Health?
The Evolent Health history is a narrative of strategic expansion and adaptation, charting a course towards a future focused on advanced healthcare solutions. The Evolent Health company background reveals a consistent drive for innovation and market leadership.
| Year | Key Event |
|---|---|
| 2011 | Evolent Health was founded by Frank Williams and Seth Blackley, marking the beginning of its journey. |
| 2013 | The company secured $100 million in Series B financing, bolstering its financial foundation. |
| 2015 | Evolent Health made its debut on the New York Stock Exchange, raising $195 million and achieving a $1 billion market capitalization. |
| 2016 | The acquisition of Valence Health expanded the company's service offerings and market reach. |
| 2019 | A strategic pivot occurred, with a renewed focus on health plan and clinical solutions. |
| 2022 | The acquisition of NIA (Magellan Specialty Health) for $650 million established a significant partnership. |
| 2023 | A rebranding to 'Evolent' unified all sub-brands under a single, specialty-focused identity. |
| 2024 | An agreement was reached to acquire AI utilization management assets from Machinify, enhancing technological capabilities. |
| Q4 2024 | Full-year revenue reached $2.55 billion, reflecting robust 30.1% growth from the previous year. |
| Q1 2025 | Five new contracts were signed, adding approximately 1 million lives and $10 million in annual revenue, with revenue reported at $483.6 million. |
| Q2 2025 | Revenue was reported at $444.3 million with Adjusted EBITDA of $37.5 million, alongside securing four additional agreements. |
| August 2025 | The company successfully refinanced its 2025 convertible notes with new notes due in 2031. |
| Q1 2026 | A national partnership with Aetna for oncology Performance Suite is scheduled to launch, covering around 250,000 Medicare Advantage lives. |
Financial Projections and Growth Targets
For 2025, Evolent Health projects revenue between $2.06 billion and $2.11 billion, anticipating organic revenue growth of 15%-18%. Adjusted EBITDA is guided to be between $135 million and $165 million.
Strategic Investments and Market Expansion
The company plans to invest approximately $35 million in capitalized software development for 2025, focusing on AI and automation for its Auth Intelligence platform and Careology App. Expansion into new specialty care categories, a market valued at $200 billion, is a key objective.
Analyst Outlook and Future Bookings
Analysts maintain a 'Buy' consensus rating with an average price target of $17.79 for 2025, expecting a return to profitability. CEO Seth Blackley anticipates a significantly increased forecast for new revenue bookings entering 2026.
Long-Term Vision and Commitment
Long-term targets include average annual revenue growth exceeding 15% and average Adjusted EBITDA growth of 20%, alongside plans to deleverage by one turn per year. This aligns with the Evolent Health mission to simplify healthcare and improve outcomes for complex conditions.
Evolent Health Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Competitive Landscape of Evolent Health Company?
- What is Growth Strategy and Future Prospects of Evolent Health Company?
- How Does Evolent Health Company Work?
- What is Sales and Marketing Strategy of Evolent Health Company?
- What are Mission Vision & Core Values of Evolent Health Company?
- Who Owns Evolent Health Company?
- What is Customer Demographics and Target Market of Evolent Health Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.